6104-45-6Relevant articles and documents
POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS
-
Page/Page column 98; 99, (2018/07/29)
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.
Discrimination between O-H...N and O-H...O=C Complexes of 3-Methyl-4-pyrimidone and Methanol. A Matrix-isolation FT-IR and Theoretical DFT/B3LYP Investigation
Muzomwe, Mayaliwa,Boeckx, Bram,Maes, Guido,Kasende, Okuma E.
experimental part, p. 23 - 33 (2012/03/27)
FT-IR matrix-isolated spectra for 3-methyl-4-pyrimidone and its H-bonded complexes with methanol in Ar were studied with the aim of discriminating between O-H...N and O-H...O=C complexes. Theoretical calculations were carried out using the DFT/B3LYP/6-31+G(d) methodology in an attempt to predict the preferred interaction site of the 3-methyl-4-pyrimidone molecule with proton donors. The observed frequency decrease of the ν(C=O) mode of 3-methyl-4-pyrimidone and the appearance of a broad (OH...O) band in the spectrum of the complex with methanol suggest that H-bonding with methanol occurs at the carbonyl group. Computed binding energies of the hydrogen-bonded complexes ( Ec) and computed intermolecular distances (r(O...H)) confirm that the O-H...O=C complex is preferred with methanol. However, for H-bonding with stronger acids such as HCl, the computational data suggest that the H-bonding occurs at the N1 ring atom of 3-methyl-4-pyrimidone.
Ozonization of thio- and azauracils
Matsui,Kamiya,Kawamura,Shibata,Muramatsu
, p. 2939 - 2941 (2007/10/02)
-